SomaLogic partners with Dante Genomics to enhance clinical and research adoption of proteomics in Europe
24 Julho 2023 - 8:30AM
SomaLogic Operating Co. Inc., (Nasdaq:SLGC), a leader in
data-driven proteomics technology, today announced its partnership
with Dante Genomics, a global leader in genomics and precision
medicine, to offer a comprehensive solution for proteomics testing
at scale in Europe. Dante will be the first SomaLogic authorized
site in Italy.
“Over the past seven years, Dante has been intensely focused on
enhancing the clinical utility of the genome, and in partnering
with SomaLogic, we will now work together to enhance the research
and discovery capabilities of the proteome,” said Andrea Riposati,
Co-founder and CEO of Dante Genomics. “By combining proteomics and
genomics, we will develop clinical insights and actionable results.
We are excited for the future of multiomics, where partnerships
like this will mean overall better healthcare for more people
around the world.”
Dante Genomics will run SomaLogic’s technology out of its
laboratory in Italy, providing proteomics services for the European
market. SomaLogic’s 7,000-plex SomaScan® Platform can be applied
across research and discovery. It can run approximately 7,000
protein measurements on a single 55 microliter plasma or serum
sample.
SomaLogic and Dante Genomics will partner to offer one of the
first multiomic capabilities to support clinical research
discovery, expanding the databases and total addressable market for
both companies.
“Italy is a leader in life science research in Europe, showing
promising growth in -omics research in academic and private
sectors,” said SomaLogic Chief Executive Officer Adam Taich. “We’re
excited to be supporting Dante Genomics’s vision for accelerating
the clinical research of proteomics.”
For more than twenty years, SomaLogic has grown from its roots
in the research lab to become a global leader in proteomics with
technology that delivers the quality and quantity of biological
insights life science researchers need - from lab to last mile.
About SomaLogic SomaLogic is catalyzing
drug research and development and biomarker identification as a
global leader in proteomics technology. With a single 55 microliter
plasma or serum sample, SomaLogic can run 7,000 protein
measurements, covering more than a third of the approximately
20,000 proteins in the human body and twice as many as other
proteomic platforms. For more than 20 years we’ve supported
pharmaceutical companies, and academic and contract research
organizations who rely on our protein detection and analysis
technologies to fuel drug, disease, and treatment discoveries in
such areas as oncology, diabetes, and cardiovascular, liver and
metabolic diseases. Find out more at www.somalogic.com and follow
@somalogic on LinkedIn.
Forward Looking Statements This press
release contains certain forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
All statements, other than statements of historical fact included
in this press release, regarding our strategy, future operations,
financial position, estimated revenues, projections, prospects,
plans and objectives of management are forward-looking statements.
These forward-looking statements generally are identified by the
words “believe,” “project,” “forecast,” “guidance,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“continue,” “will likely result,” “possible,” “potential,”
“predict,” “pursue,” “target” and similar expressions, although not
all forward-looking statements contain such identifying words.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Forward-looking statements do not guarantee
future performance and involve known and unknown risks,
uncertainties and other factors. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this press release, including factors which are
beyond SomaLogic’s control. You should carefully consider these
risks and uncertainties, including, but not limited to, those
factors described under Part I, Item 1A – “Risk Factors” in our
Annual Report on Form 10-K and other filings we make with the
Securities and Exchange Commission. These filings identify and
address important risks and uncertainties that could cause actual
events and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and SomaLogic assumes
no obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Should one or more of these risks or
uncertainties materialize, or should any of the assumptions prove
incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. The Company will not
and does not undertake any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required under
applicable securities laws.
Dante Genomics ContactLaura D’AngeloVP of
Investor Relationsir@dantelabs.com+39 0862 191
0671www.dantegenomics.com
SomaLogic Media ContactEmilia
Costales720-798-5054ecostales@somalogic.com
SomaLogic Investor ContactMarissa BychGilmartin
Group LLCinvestors@somalogic.com
SomaLogic (NASDAQ:SLGC)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
SomaLogic (NASDAQ:SLGC)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024